The use of a low molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin dependent thrombocytopenia and thrombosis.
We report two cases of heparin induced thrombocytopenia (HIT), in patients who required anticoagulation for extracorporeal procedures (haemodialysis and cardiopulmonary bypass) one associated with recurrent thrombosis of the artificial circuits. Resolution of thrombocytopenia and successful anticoagulation were achieved using a low molecular weight heparinoid (LMWH) Org 10172. Anticoagulation was monitored using estimations of plasma anti-factor Xa activity. These cases demonstrate that LMWH provides safe and effective anticoagulation in patients in whom unfractionated heparin has caused HIT.
Rowlings
P A
PA
Department of Haematology, Prince Henry Hospital, Sydney, NSW.
Mansberg
R
R
Rozenberg
M C
MC
Evans
S
S
Murray
B
B
D000368:Aged; D002315:Cardiopulmonary Bypass; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006493:Heparin / Q000009:adverse effects*; D006496:Heparinoids / Q000627:therapeutic use*; D006497:Heparan Sulfate; D006801:Humans; D006435:Renal Dialysis; D013921:Thrombocytopenia / Q000139:chemically induced*; D013927:Thrombosis / Q000139:chemically induced*
D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D005343:Fibrinolytic Agents; D006025:Glycosaminoglycans; D006493:Heparin; D006496:Heparinoids; D006497:Heparan Sulfate; C035838:danaparoid